{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:30Z","timestamp":1792612290467,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ebiom.2021.103240","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T06:09:21Z","timestamp":1612937361000},"page":"103240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)"],"prefix":"10.1016","volume":"64","author":[{"given":"Shuguang","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-0730","authenticated-orcid":false,"given":"Bohao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anxian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkai","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2021.103240_bib0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2017.00202","article-title":"Oncolytic viruses-natural and genetically engineered cancer immunotherapies","volume":"7","author":"Jhawar","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0002","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic viruses: from bench to bedside with a focus on safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ebiom.2021.103240_bib0003","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic viruses and immune checkpoint inhibitors: preclinical developments to clinical trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2021.103240_bib0005","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2021.103240_bib0006","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2021.103240_bib0007","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2021.103240_bib0008","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0009","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.omto.2019.10.003","article-title":"Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1","volume":"15","author":"Zhu","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ebiom.2021.103240_bib0010","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2021.103240_bib0011","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2021.103240_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0013","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1220467","article-title":"Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition","volume":"5","author":"Kleinpeter","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ebiom.2021.103240_bib0014","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunpaa","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","article-title":"Intratumoral delivery of a PD-1-blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ebiom.2021.103240_bib0016","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2021.103240_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0018","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","article-title":"Oncolytic viruses and immune checkpoint inhibition: the best of both worlds","volume":"13","author":"Sivanandam","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ebiom.2021.103240_bib0020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2017.00555","article-title":"Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives","volume":"8","author":"Guo","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ebiom.2021.103240_bib0022","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1128\/jvi.61.6.1788-1795.1987","article-title":"High-frequency homologous recombination in vaccinia virus DNA","volume":"61","author":"Ball","year":"1987","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0023","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.ebiom.2021.103240_bib0024","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdy507","article-title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","volume":"30","author":"Oliva","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0025","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","article-title":"Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade","volume":"25","author":"Chon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2021.103240_bib0026","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ebiom.2021.103240_bib0027","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","article-title":"Recombinant adenovirus expressing a soluble fusion protein PD-1\/CD137L subverts the suppression of CD8(+) T cells in HCC","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2021.103240_bib0028","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ebiom.2021.103240_bib0029","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","article-title":"Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity","volume":"200","author":"Dixon","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0031","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0032","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2021.103240_bib0033","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 axis regulates human T cell function","volume":"188","author":"Lozano","year":"2012","journal-title":"J Immunol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:01:55Z","timestamp":1762455715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"alternative-id":["S2352396421000335"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103240","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103240"}}